Want to see AU:PHX full AI Analyst Report?
PHX Stock Chart & Stats
AU$0.10
<AU$0.01(5.00%)
At close: 4:00 PM EST
AU$0.10
<AU$0.01(5.00%)
Day’s Range― - ―
52-Week RangeAU$0.08 - AU$0.20
Previous CloseN/A
Volume723.89K
Average Volume (3M)304.65K
Market Cap
AU$62.18M
Enterprise ValueAU$79.67
Total Cash (Recent Filing)AU$2.57M
Total Debt (Recent Filing)AU$540.00K
Price to Earnings (P/E)―
Beta0.75
Next Earnings
Feb 25, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield6.52%
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding668,618,650
10 Day Avg. Volume508,382
30 Day Avg. Volume304,650
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)3.46
Price to Sales (P/S)10.58
P/FCF Ratio100.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservatively Levered Balance SheetVery low leverage reduces the company’s dependence on debt financing and limits interest-related pressure on future cash flows. This gives PharmX greater flexibility to absorb operating weakness, preserve capital, and fund business priorities without immediate balance-sheet strain.
Positive Operating And Free Cash Flow In 2026Positive operating and free cash flow provide evidence that the business generated cash internally during 2026 despite reporting a net loss. If maintained, this can support ongoing operations and reduce reliance on external funding, although consistency remains important.
Expanding Equity And Asset BaseGrowth in equity and total assets indicates a stronger capital base than the prior year. This improves financial resilience and provides more resources to support operations, while also giving management greater capacity to address the company’s profitability challenges.
Bears Say
Revenue Contraction And Gross LossA material revenue decline combined with a shift from gross profit to gross loss signals weakening commercial performance and reduced underlying operating efficiency. Unless reversed, this can constrain the company’s ability to cover overheads and rebuild sustainable earnings.
Widening Losses And Deteriorating MarginsThe sharp deterioration in net margin and operating performance shows that losses are becoming more significant relative to revenue. Persistent negative profitability can consume the company’s capital base over time and limit its ability to invest while funding operations internally.
Volatile Cash GenerationThe swing from very large cash outflows in 2025 to positive cash flow in 2026 demonstrates meaningful volatility in cash generation. That inconsistency makes funding capacity less predictable and raises questions about whether recent cash conversion can be sustained.
PharmX Technologies News
PHX FAQ
What was PharmX Technologies Limited’s price range in the past 12 months?
PharmX Technologies Limited lowest share price was AU$0.08 and its highest was AU$0.20 in the past 12 months.
What is PharmX Technologies Limited’s market cap?
PharmX Technologies Limited’s market cap is AU$62.18M.
When is PharmX Technologies Limited’s upcoming earnings report date?
PharmX Technologies Limited’s upcoming earnings report date is Feb 25, 2027 which is in 147 days.
How were PharmX Technologies Limited’s earnings last quarter?
PharmX Technologies Limited released its earnings results on Aug 26, 2026. The company reported -AU$0.002 earnings per share for the quarter.
Is PharmX Technologies Limited overvalued?
According to Wall Street analysts PharmX Technologies Limited’s price is currently Overvalued.
Does PharmX Technologies Limited pay dividends?
PharmX Technologies Limited pays a Notavailable dividend of AU$0.007 which represents an annual dividend yield of 6.52%. See more information on PharmX Technologies Limited dividends here
What is PharmX Technologies Limited’s EPS estimate?
PharmX Technologies Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PharmX Technologies Limited have?
PharmX Technologies Limited has 668,618,650 shares outstanding.
What happened to PharmX Technologies Limited’s price movement after its last earnings report?
PharmX Technologies Limited reported an EPS of -AU$0.002 in its last earnings report. Following the earnings report the stock price went down -4.762%.
Which hedge fund is a major shareholder of PharmX Technologies Limited?
Currently, no hedge funds are holding shares in AU:PHX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PharmX Technologies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-31.11%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
44.86%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
PharmX Technologies Limited
PharmX Technologies Limited, together with its subsidiaries, operates as a technology and software development company in Australia. It also operates PharmX, an electronic ordering and invoicing gateway; PharmX Marketplace, an e-commerce ordering platform; PharmX Analytics which provides insights for operations of supplier and pharmacy customers. The company was formerly known as Corum Group Limited and changed its name to PharmX Technologies Limited in October 2023. PharmX Technologies Limited was incorporated in 1950 and is headquartered in Sydney, Australia.
Technical Analysis
Beamtree Holdings Ltd
―
MedAdvisor Limited
―
Alcidion Group Limited
―
InteliCare Holdings Limited
―
PainChek Ltd
―